Condition: Heart Failure · Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy · Sponsor: Universitaire Ziekenhuizen KU Leuven
Preliminary data suggests that patients suffering from advanced refractory heart failure (HF) could benefit from single low dose whole heart external beam radiotherapy (EBRT). Objective: To explore in our center the efficacy of administering a EBRT treatment of 5Gy to the whole heart in patients with advanced and refractory HF. The hypothesis is that 5Gy EBRT to the whole heart can improve the left ventricular ejection fraction (LVEF) of these patients by a clinically relevant 5%. Main study endpoints: The primary aim is to explore the efficacy of EBRT treatment for advanced refractory HF. Secondary endpoints include an assessment of safety, overall survival, hospital admissions, late toxicity, quality of life and the effect of the treatment on other heart function indicators (left ventricular volumes, NT-proBNP, Troponine, High sensitive CRP).
This description comes directly from the study's public registry record.
Patrick Berkovic, MD PhD · +32 16 34 51 15 · patrick.berkovic@uzleuven.be
Bert Vandenberk, MD PhD · +32 16 33 86 86 · bert.vandenberk@uzleuven.be
Always discuss trial participation with your own doctor first.
| UZ Leuven | Leuven, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06661876